Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.

Journal of the American Society of Nephrology : JASN
M OtsB M Brenner

Abstract

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) slow the rate of progression of experimental renal disease. Although the end result of both classes of drugs is to block the renin-angiotensin system (RAS), ACEI and AT1RA act at different sites in the RAS cascade. The aim of this study was to compare the effects of an ACEI (enalapril) and AT1RA (losartan), alone or in combination, in slowing the progression of experimental renal disease in a model of reduced renal mass. Two weeks after 5/6 renal ablation, rats were divided into five groups matched for body weight, systolic BP (SBP), and urinary protein excretion rate (UprotV). The effects on SBP and UprotV of treatment with 25 and 40 mg/L enalapril (groups I and II; both n = 7), 180 mg/L losartan (group III, n = 8), or a combination of enalapril (25 mg/L) + losartan (180 mg/L) (group IV, n = 9) versus vehicle (group V, n = 9) were studied for 12 wk. Remnant kidneys were then assessed histologically for evidence of focal and segmental glomerulosclerosis and hyalinosis (FSGS), and interstitial fibrosis. There were no significant differences (NSD) in body weight among the groups at any time. Combination therapy reduced SBP (122 +/- 8 m...Continue Reading

Citations

Jun 10, 2000·Current Opinion in Nephrology and Hypertension·A B Fogo
Jun 28, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J L Wilkinson-BerkaD J Kelly
Sep 7, 1999·Journal of the American Society of Nephrology : JASN·A BesarabJ Yee
Jan 5, 2000·Kidney International·P T PhamS Q Lew
Jan 5, 2000·Kidney International·J H DominguezR Peterson
May 3, 2000·Kidney International·M W Taal, B M Brenner
Jun 8, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·M OtsA Tamm
Mar 22, 2001·Kidney International·L A HebertB H Rovin
May 30, 2001·Lancet·P RuggenentiG Remuzzi
Sep 20, 2001·Journal of the American Society of Nephrology : JASN·Maarten W TaalBarry M Brenner
Sep 20, 2001·Journal of the American Society of Nephrology : JASN·Norma A BobadillaJaime Herrera-Acosta
Apr 23, 2002·Kidney International·Mahmood S Mozaffari, Stephen W Schaffer
Mar 28, 2003·Journal of the American Society of Nephrology : JASN·Peter JacobsenHans-Henrik Parving
Jul 10, 2002·Current Opinion in Nephrology and Hypertension·Maarten W Taal, Barry M Brenner
Dec 5, 1998·Kidney International. Supplement·M Burnier, H R Brunner
Aug 8, 2002·Diabetes Technology & Therapeutics·Geoffrey BonerMark E Cooper
Sep 28, 2002·Journal of Cardiovascular Pharmacology·Kazunori YoshidaMasahiro Kohzuki
Apr 11, 2001·Journal of Internal Medicine·E RitzJ Wagner
Jun 4, 1999·Journal of Clinical Pharmacology·M M McConnaugheyA J Ingenito
Dec 18, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoru KuriyamaTatsuo Hosoya
Feb 12, 2004·Kidney International·Karina SotoJesús Egido
Dec 2, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mieneke RookGerjan Navis
Feb 15, 2001·Circulation·M Burnier
Mar 13, 2003·Kidney International·Edwina K RiceDavid J Nikolic-Paterson
Mar 12, 2004·Nephrology·Chollada BuranakarlKenneth C Bovee
Jan 28, 2005·Zeitschrift für Kardiologie·M-L GrossE Ritz
Mar 5, 2005·American Journal of Nephrology·Mark E Williams
Oct 14, 2005·Kidney International·Maria Heloisa Massola ShimizuAntonio Carlos Seguro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.